Polycystic ovary syndrome has long been framed as a reproductive disorder, a condition defined by irregular cycles, elevated male hormones, and the ovarian cysts that give it its name. A new systematic review and meta-analysis published in BMC Endocrine Disorders argues that this framing is dangerously incomplete. Drawing on a decade-spanning search of PubMed, Web of Science, and Google Scholar through February 2026, researchers Yazeed Albalawi and Hyder Mirghani of the University of Tabuk in Saudi Arabia pooled data from ten studies and found that women with PCOS carry a measurably heavier psychiatric burden than women without the syndrome, spanning depression, suicidal thoughts, and, most strikingly, suicide attempts.
The scale of the underlying condition makes the findings consequential. PCOS affects roughly ten percent of women of reproductive age, making it one of the most common endocrine disorders worldwide. Its core features, infertility, hyperandrogenism, and insulin resistance, are well documented in the metabolic literature, but the authors argue that these same physiological disruptions may feed directly into psychological distress. Chronic anovulation and infertility carry profound social and emotional weight, while hyperandrogenic symptoms such as hirsutism and acne can erode body image and self-esteem. Insulin resistance, meanwhile, has been repeatedly linked in broader research to mood disturbance, offering a plausible biological bridge between the ovaries and the brain.
To test that connection rigorously, the researchers followed the PRISMA reporting framework, the international standard for systematic reviews. Their initial search retrieved 209 articles. After removing duplicates, 27 records remained for closer inspection, and 17 full texts were screened against predefined eligibility criteria. Ultimately, ten studies met the quality bar for quantitative synthesis. The team used the odds ratio as its principal statistical instrument, a measure that compares the odds of an outcome occurring in the PCOS group against the odds in controls, with values above one indicating elevated risk. Confidence intervals were calculated at the conventional 95 percent level, meaning there is a one in twenty chance that the true effect lies outside the reported range.
The headline numbers are sobering. Suicidal ideation, the experience of thinking about or planning suicide, was elevated in women with PCOS with an odds ratio of 1.11 and a 95 percent confidence interval of 1.01 to 1.21. That interval sits entirely above the null value of one, which in meta-analytic terms means the association is statistically significant, though modest in magnitude. Depression showed a similar pattern, with an odds ratio of 1.17 and a confidence interval of 1.08 to 1.27, again a statistically reliable but comparatively small elevation. On their own, these figures suggest that for every group of women with PCOS, a slightly larger share experiences depressive symptoms and suicidal thoughts than a comparable group without the syndrome.
The most dramatic result, however, concerned suicide attempts. Here the authors reported a log odds ratio of 4.98 with a 95 percent confidence interval of 1.32 to 18.88. Because the interval is extremely wide, the precision of this estimate is limited, a common feature when the outcome is statistically rare and the number of contributing studies is small. Yet the direction and size of the effect are difficult to dismiss. When the researchers performed a subgroup analysis and removed a single study that contributed disproportionately to heterogeneity, the statistical variability across included trials, the estimate grew even stronger, reaching a log odds ratio of 8.47 with a confidence interval of 7.55 to 9.50. In plain terms, after accounting for the most variable study, the signal linking PCOS to attempted suicide became both more powerful and more precise.
Heterogeneity is the central technical challenge in any meta-analysis, and the authors were transparent about confronting it. When individual studies differ in their populations, diagnostic criteria, and measurement tools, pooling their results can produce estimates that are mathematically valid but clinically ambiguous. The team applied GRADE, the Grading of Recommendations Assessment, Development and Evaluation system, to assess the certainty of their evidence, and they used sensitivity analyses to test whether any single study was driving the overall result. The fact that the suicide attempt association strengthened, rather than collapsed, when the high-heterogeneity study was excluded suggests the finding is not an artifact of one outlier dataset. Still, the authors are careful to note that the evidence base remains limited and, in places, inconsistent, echoing the very gap their review was designed to address.
The diagnostic landscape of PCOS itself complicates interpretation. Over the decades, the field has operated under competing frameworks, including criteria from the National Institutes of Health and the Androgen Excess Society, each of which defines the syndrome slightly differently. Studies included in a meta-analysis may therefore enroll subtly different patient populations, some emphasizing oligomenorrhea and hyperandrogenism, others incorporating polycystic ovarian morphology on ultrasound. Body mass index adds another layer, since obesity is both more prevalent in PCOS and independently associated with depression. Without uniform adjustment for BMI across the included studies, some of the observed psychiatric risk could reflect metabolic comorbidity rather than PCOS per se, a caveat the authors implicitly acknowledge in their call for further research.
What makes the paper clinically urgent is its implication for screening. Mental health assessment is not currently a routine component of endocrine care for PCOS in most settings, where clinical attention tends to focus on menstrual regulation, fertility treatment, and metabolic management. The authors argue that their findings should inform mental health screening and suicide prevention specifically in affected women, effectively proposing that a gynecological or endocrinology appointment could serve as a critical checkpoint for identifying patients at psychological risk. Given that PCOS is diagnosed in young women, often in their teens or twenties, and persists across the reproductive lifespan, the cumulative exposure to untreated depression could be substantial. The authors explicitly state that further prospective studies investigating the prevalence of depression and suicide in PCOS are needed to determine the best treatment approaches.
The biological plausibility of a PCOS-brain connection deserves attention in its own right. Hyperandrogenism, the excess of androgens such as testosterone, has been studied for its effects on mood regulation, with evidence pointing in complex and sometimes contradictory directions. Insulin resistance alters cerebral glucose metabolism and has been implicated in the pathophysiology of depression in general populations. Chronic low-grade inflammation, another hallmark of PCOS, is increasingly recognized as a contributor to depressive disorders. Add the psychological load of infertility, unwanted hair growth, weight gain, and the social pressures that surround them, and the syndrome presents a convergence of biological and psychosocial risk factors that few other common conditions replicate. The meta-analysis does not disentangle these mechanisms, but it establishes the epidemiological signal that future mechanistic work must now explain.
For the estimated one in ten women of reproductive age living with PCOS, the study reframes the condition as a whole-body, whole-mind disorder rather than a purely gynecological one. The authors, who self-funded the work and declared no competing interests, published their findings open access, making the evidence freely available to clinicians and patients alike. Their synthesis of ten studies, filtered from an initial pool of 209, represents one of the most focused quantitative examinations to date of suicidality in this population. The message for medicine is direct: the psychiatric dimensions of PCOS, particularly the elevated risk of suicide attempts, can no longer be treated as incidental. Whether routine screening in endocrine and obstetric clinics can translate these statistics into lives saved is now the question that prospective research, and health systems, must answer.
Subject of Research: Association between polycystic ovary syndrome and depression and suicidality in women
Article Title: Suicidality and depression in women with polycystic ovary syndrome: a systematic review and meta-analysis
Article References: Albalawi, Y., & Mirghani, H. (2026). Suicidality and depression in women with polycystic ovary syndrome: a systematic review and meta-analysis. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02554-x
Image Credits: AI Generated
DOI: 10.1186/s12902-026-02554-x
Keywords: polycystic ovary syndrome, PCOS, depression, suicidal ideation, suicide attempts, meta-analysis, systematic review, mental health, hyperandrogenism, insulin resistance, women’s health, endocrine disorders
Tags: Depressionendocrine disordersHyperandrogenisminsulin resistanceMental HealthMeta-analysisPCOSPolycystic ovary syndromesuicidal ideationsuicide attemptssystematic reviewwomen’s health
